Cesar Alexander Ortiz Rojas, Diego Antonio Pereira-Martins, Candy Christie Bellido More, Dominique Sternadt, Isabel Weinhäuser, Jacobien R Hilberink, Juan Luiz Coelho-Silva, Carolina Hassibe Thomé, Germano Aguiar Ferreira, Emanuele Ammatuna, Gerwin Huls, Peter J Valk, Jan Jacob Schuringa, Eduardo Magalhães Rego
Despite advancements in utilizing genetic markers to enhance acute myeloid leukaemia (AML) outcome prediction, significant disease heterogeneity persists, hindering clinical management. To refine survival predictions, we assessed the transcriptome of non-acute promyelocytic leukaemia chemotherapy-treated AML patients from five cohorts (n = 975). This led to the identification of a 4-gene prognostic index (4-PI) comprising CYP2E1, DHCR7, IL2RA and SQLE. The 4-PI effectively stratified patients into risk categories, with the high 4-PI group exhibiting TP53 mutations and cholesterol biosynthesis signatures...
April 23, 2024: British Journal of Haematology